Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07282470
Active, not recruiting Observational

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND

NCT07282470 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase
Observational
Started
2024-09-25
Last updated
2026-08-28

Condition(s) studied

MeningiomaMeningioma of Brain

Study summary

Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Inclusion Criteria (Retrospective \& Prospective): * Patient aged 18 years or older. * First diagnosis of uni-focal meningioma of the convexity. * Macroscopical total resection (Simpson 1-3). (Retrospective only): * Surgery performed between 2007 and 2016; * availability of FFPE sample and medical records. Exclusion Criteria: * Genetic syndromes. * Diffuse Meningeal Meningiomatosis. * Patients who underwent experimental treatment in neo-adjuvant setting. (Prospective only): * Previous surgical/medical treatment for another meningioma; * positive oncological history (e.g., breast cancer).

Primary outcome measure(s)

  • Definition of a novel epigenetic signature based on MS-profiling — Months 1-12
    Identification of histone post-translational modifications (PTMs) patterns in FFPE tissue samples capable of classifying tumor recurrence.

Trial sites (1)

FacilityCityRegionStatus
Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy

More Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials in Italy

Neuropsychological Profile Characterization in Patients With Migraine: Cognitive Functioning and Psychological Variables Recruiting
Psychological and Psychiatric Assessment in Patients Eligible for Epilepsy Surgery Recruiting
Study for the Diagnosis and Treatment of Drug-resistant Focal Epilepsies Recruiting
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP Recruiting
COMparative Performance of General Purpose Models Recruiting

Other trials for the same condition

Predictive Factors for Survival in Aggressive Meningiomas Recruiting
Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07282470 on ClinicalTrials.gov ↗ ← All trials in Italy